StocksFundsScreenerSectorsWatchlists
MRSN

MRSN - Mersana Therapeutics Inc Stock Price, Fair Value and News

4.48USD-0.01 (-0.22%)Market Closed

Market Summary

MRSN
USD4.48-0.01
Market Closed
-0.22%

MRSN Alerts

  • Big fall in Revenue (Y/Y)
  • Big jump in Earnings (Y/Y)
  • Losses in recent quarter

MRSN Stock Price

View Fullscreen

MRSN RSI Chart

MRSN Valuation

Market Cap

543.4M

Price/Earnings (Trailing)

-3.17

Price/Sales (Trailing)

14.75

Price/Free Cashflow

-3.18

MRSN Price/Sales (Trailing)

MRSN Profitability

Return on Equity

-465.22%

Return on Assets

-75.95%

Free Cashflow Yield

-31.48%

MRSN Fundamentals

MRSN Revenue

Revenue (TTM)

36.9M

Rev. Growth (Yr)

-27.14%

Rev. Growth (Qtr)

39.01%

MRSN Earnings

Earnings (TTM)

-171.7M

Earnings Growth (Yr)

56.46%

Earnings Growth (Qtr)

53.05%

Breaking Down MRSN Revenue

Last 7 days

-11.1%

Last 30 days

18.2%

Last 90 days

93.1%

Trailing 12 Months

8.5%

How does MRSN drawdown profile look like?

MRSN Financial Health

Current Ratio

3.36

Debt/Equity

0.63

Debt/Cashflow

-7.3

MRSN Investor Care

Shares Dilution (1Y)

12.29%

Diluted EPS (TTM)

-1.49

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202332.3M38.7M40.8M36.9M
202211.1M16.3M21.4M26.6M
20210006.0M
2020028.4M14.6M828.0K
201948.6M44.6M43.3M42.1M
201816.3M16.8M12.7M10.6M
201725.8M23.3M26.3M17.5M
201614.1M17.8M21.5M25.2M
201500010.4M

Tracking the Latest Insider Buys and Sells of Mersana Therapeutics Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jan 16, 2024
lowinger timothy b
sold
-28,208
2.71
-10,409
svp, chief sci.&tech. officer
Jan 16, 2024
misra tushar
sold
-9,097
2.71
-3,357
svp, chief manuf. officer
Jan 16, 2024
deschuytner brian
sold
-25,276
2.71
-9,327
svp, coo & cfo
Jan 16, 2024
bala mohan
sold
-9,298
2.71
-3,431
svp, chief development officer
Jan 16, 2024
mandelia ashish
sold
-13,617
2.71
-5,025
vp, chief accounting officer
Jan 16, 2024
protopapas anna
sold
-79,671
2.71
-29,399
-
Jan 16, 2024
carvajal alejandra
sold
-11,872
2.71
-4,381
svp, chief legal officer
Jan 15, 2024
protopapas anna
acquired
-
-
38,958
-
Jan 15, 2024
lowinger timothy b
acquired
-
-
15,208
svp, chief sci.&tech. officer
Jan 15, 2024
mandelia ashish
acquired
-
-
5,352
vp, chief accounting officer

1–10 of 50

Which funds bought or sold MRSN recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Mar 22, 2024
PNC FINANCIAL SERVICES GROUP, INC.
new
-
464
464
-%
Mar 11, 2024
VANGUARD GROUP INC
added
0.83
6,614,830
14,471,200
-%
Mar 01, 2024
GOLDMAN SACHS GROUP INC
reduced
-13.62
247,365
675,422
-%
Mar 01, 2024
READYSTATE ASSET MANAGEMENT LP
new
-
684,488
684,488
0.02%
Feb 28, 2024
AMERICAN INTERNATIONAL GROUP, INC.
added
4.93
61,151
127,851
-%
Feb 26, 2024
Virtu Financial LLC
sold off
-100
-28,000
-
-%
Feb 16, 2024
GSA CAPITAL PARTNERS LLP
sold off
-100
-129,000
-
-%
Feb 16, 2024
PUBLIC EMPLOYEES RETIREMENT SYSTEM OF OHIO
new
-
36,656
36,656
-%
Feb 16, 2024
PRICE T ROWE ASSOCIATES INC /MD/
reduced
-13.94
63,000
174,000
-%
Feb 15, 2024
Farther Finance Advisors, LLC
new
-
2.00
2.00
-%

1–10 of 48

Are Funds Buying or Selling MRSN?

Are funds buying MRSN calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own MRSN
No. of Funds

Unveiling Mersana Therapeutics Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
silverarc capital management, llc
5.3%
6,420,136
SC 13G
Feb 14, 2024
venrock healthcare capital partners iii, l.p.
9.4%
11,328,000
SC 13G/A
Feb 14, 2024
avoro capital advisors llc
0%
0
SC 13G/A
Feb 14, 2024
balyasny asset management l.p.
8.04%
9,698,147
SC 13G
Feb 14, 2024
orbimed advisors llc
0.0%
0
SC 13G/A
Feb 13, 2024
vanguard group inc
5.17%
6,237,588
SC 13G
Jan 29, 2024
blackrock inc.
6.5%
7,844,282
SC 13G/A
Jan 22, 2024
state street corp
1.93%
2,329,434
SC 13G/A
Aug 07, 2023
venrock healthcare capital partners iii, l.p.
8.5%
9,678,000
SC 13G
Jul 27, 2023
ecor1 capital, llc
16.9%
19,364,688
SC 13G

Recent SEC filings of Mersana Therapeutics Inc

View All Filings
Date Filed Form Type Document
Feb 28, 2024
10-K
Annual Report
Feb 28, 2024
424B5
Prospectus Filed
Feb 28, 2024
8-K
Current Report
Feb 28, 2024
8-K
Current Report
Feb 28, 2024
POS AM
POS AM
Feb 28, 2024
POSASR
POSASR
Feb 16, 2024
4/A
Insider Trading
Feb 14, 2024
SC 13G
Major Ownership Report
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 14, 2024
SC 13G/A
Major Ownership Report

Peers (Alternatives to Mersana Therapeutics Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
40.7B
6.8B
10.47% -29.37%
-8.64
5.95
-64.45% -156.37%
22.4B
152.6K
-0.77% 465779.94%
-2.4K
146.8K
- -9.98%
18.8B
1.8B
-5.20% -21.33%
-42.76
10.3
76.23% 61.08%
16.5B
2.4B
-4.27% -3.75%
98.3
6.81
15.42% 18.43%
12.8B
3.7B
-5.97% -18.88%
21.4
3.46
8.87% 75.42%
MID-CAP
7.1B
396.6M
-14.15% -6.74%
-13.41
17.87
425.83% 18.94%
5.4B
-
-9.06% 107.52%
-8.32
60.35
54.84% -34.79%
3.8B
270.6M
1.09% 28.79%
-15.8
13.97
440.80% -27.84%
3.5B
240.7M
-9.47% 17.74%
-11.94
14.72
-1.03% -92.09%
3.0B
726.4M
-25.38% 1.37%
-49.71
4.19
40.45% 71.62%
SMALL-CAP
1.9B
398.2M
13.53% -1.12%
26.31
4.72
85.90% -14.05%
669.0M
983.7M
-9.64% -20.86%
-1.23
0.68
-50.36% 17.16%
411.7M
881.7K
52.39% 472.85%
-9.23
466.16
-77.61% -5.33%
324.4M
4.9M
76.14% 20.49%
-2.4
66.66
-54.97% 51.72%
14.1M
2.1M
238.33% 93.33%
-0.52
2.14
-13.45% 66.37%

Mersana Therapeutics Inc News

Latest updates
MarketBeat26 Mar 202402:40 am
CNN25 Mar 202410:49 pm

Mersana Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42020Q42020Q32020Q22019Q42019Q32019Q22019Q12018Q42018Q32018Q22018Q12017Q4
Revenue39.0%10,7017,69810,6547,80214,6885,5734,2842,0361,02411.0021.0032.0042.0084420241,0351,1892,1514,1913,0643,261
Operating Expenses-37.8%32,12851,63967,15565,60360,51465,21256,03448,58848,04228,77222,42720,58416,64218,13717,95819,58623,96819,56016,89415,827-
  S&GA Expenses-21.4%10,13412,89418,18718,32814,80514,57314,80312,78210,6745,9145,8815,1714,2124,4364,1924,4434,1524,3804,2313,571-
  R&D Expenses-29.6%21,49530,53148,96847,27545,70950,63941,23135,80637,36822,85816,54615,41312,43013,70113,76615,14319,81615,18012,66312,256-
Interest Expenses3.0%1,0481,0171,02598396488076072498192.0092.0087.0087.0010740.00------
Net Income53.1%-19,557-41,656-54,307-56,163-44,918-59,811-52,219-47,258-48,983-28,844-22,489-19,786-16,246-16,792-17,07121,901-22,431-17,069-12,354-12,403-
Net Income Margin3.4%-4.66*-4.82*-5.56*-6.59*-7.68*-251.54*-234.22*-220.56*-205.39*------------
Free Cashflow30.5%-32,348-46,553-62,233-29,916-52,01454,171-45,433-8,284-42,555------------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Assets-14.0%22626331129633431525225820621825424827329031196.0010812213914979.00
  Current Assets-14.3%21425029728231930023724118919923323225927529580.0010111513214174.00
    Cash Equivalents-6.3%17518612912312918413523017819222722825527128860.0063.0058.0011613760.00
  Net PPE-----4.00---2.00---2.002.002.002.002.002.003.003.003.00
Liabilities-10.2%18921122123224222511811884.0062.0058.0050.0045.0037.0037.0033.0029.0029.0031.0025.0070.00
  Current Liabilities-6.3%64.0068.0075.0083.0092.0089.0071.0056.0048.0044.0040.0035.0030.0021.0022.0017.0024.0022.0024.0023.0069.00
  Short Term Borrowings-2.00--------------------
  Long Term Debt-8.0%23.0025.0025.0025.0025.0025.0025.0025.0025.005.005.005.005.005.003.004.004.005.005.00--
    LT Debt, Current-----------0.00---2.001.001.000.00---
    LT Debt, Non Current-23.00---25.00---25.00---5.005.003.004.004.005.005.00--
Shareholder's Equity-29.3%37.0052.0090.0064.0092.0090.0013414112215619619822825327463.0078.0093.001091249.00
  Retained Earnings-2.4%-826-806-765-710-654-609-549-497-450-401-356-315-280-251-229-209-192-176-159-142-164
  Additional Paid-In Capital0.5%863859855775747700684638572557552513508505503272271269268266173
Shares Outstanding0.1%12112112010910598.0088.0080.0071.0070.0069.0069.00---------
Float---364---403---800---1,148---164--
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations30.6%-31,962-46,081-61,834-29,005-51,22954,597-44,776-7,955-42,400-36,098-34,468-27,022-17,319-20,196-15,935-21,246-12,576-16,284-14,197-24,687-15,904
  Share Based Compensation2.1%4,0854,0016,6436,4075,3145,3755,3485,4854,8604,9284,5824,0391,9891,9181,6561,6091,2621,2851,1611,1641,128
Cashflow From Investing-80.6%20,148103,778-5,4391,396-45,426-16,491-90,470-329-155-46.00-333-114-1882,80514,97519,43516,500-41,768-12,15310,12813,723
Cashflow From Financing163.0%92.00-14673,18021,54941,45810,63840,52760,39428,79546333,9164721,665-49.00228,886-90.00231-8.005,27792,204211

MRSN Income Statement

2023-12-31
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Income Statement [Abstract]   
Collaboration revenue$ 36,855$ 26,581$ 43
Operating expenses:   
Research and development148,269173,385132,013
General and administrative59,54356,96336,888
Restructuring expenses8,71300
Total operating expenses216,525230,348168,901
Other income (expense):   
Interest income12,0732,88365
Interest expense(4,073)(3,328)(1,267)
Total other income (expense), net8,000(445)(1,202)
Net loss(171,670)(204,212)(170,060)
Other comprehensive loss:   
Unrealized gain (loss) on marketable securities163(152)0
Comprehensive loss(171,507)(204,364)(170,060)
Net loss attributable to common stockholders - basic(171,670)(204,212)(170,060)
Net loss attributable to common stockholders - diluted$ (171,670)$ (204,212)$ (170,060)
Net loss per share attributable to common stockholders — basic (in dollars per share)$ (1.48)$ (2.18)$ (2.41)
Net loss per share attributable to common stockholders — diluted (in dollars per share)$ (1.48)$ (2.18)$ (2.41)
Weighted-average number of shares of common stock used in net loss per share attributable to common stockholders — basic (in shares)116,112,89193,654,24370,580,949
Weighted-average number of shares of common stock used in net loss per share attributable to common stockholders — diluted (in shares)116,112,89193,654,24370,580,949

MRSN Balance Sheet

2023-12-31
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 174,561$ 128,885
Short-term marketable securities34,523151,827
Accounts receivable030,000
Prepaid expenses and other current assets4,9738,507
Total current assets214,057319,219
Property and equipment, net3,8313,985
Operating lease right-of-use assets7,69410,475
Other assets, noncurrent478661
Total assets226,060334,340
Current liabilities:  
Accounts payable7,31913,951
Accrued expenses21,89843,184
Deferred revenue28,14730,610
Operating lease liabilities3,2522,798
Short-term debt2,0830
Other current liabilities938990
Total current liabilities63,63791,533
Operating lease liabilities, noncurrent5,1498,575
Long-term debt, net23,14824,929
Deferred revenue, noncurrent97,167117,043
Other liabilities, noncurrent55203
Total liabilities189,156242,283
Commitments (Note 15)
Stockholders' equity  
Preferred stock, $0.0001 par value; 25,000,000 shares authorized; 0 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively00
Common stock, $0.0001 par value; 350,000,000 shares authorized; 120,711,745 and 105,144,864 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively1211
Additional paid-in capital863,242746,889
Accumulated other comprehensive income (loss)11(152)
Accumulated deficit(826,361)(654,691)
Total stockholders’ equity36,90492,057
Total liabilities and stockholders’ equity$ 226,060$ 334,340
Common stock, shares authorized (in shares)350,000,000350,000,000
MRSN
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has a research and development collaborations with Janssen Biotech, Inc. and Merck KGaA, as well as collaboration agreement with Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.
 CEO
 WEBSITEwww.mersana.com
 EMPLOYEES228

Mersana Therapeutics Inc Frequently Asked Questions


What is the ticker symbol for Mersana Therapeutics Inc? What does MRSN stand for in stocks?

MRSN is the stock ticker symbol of Mersana Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Mersana Therapeutics Inc (MRSN)?

As of Thu Mar 28 2024, market cap of Mersana Therapeutics Inc is 543.44 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of MRSN stock?

You can check MRSN's fair value in chart for subscribers.

What is the fair value of MRSN stock?

You can check MRSN's fair value in chart for subscribers. The fair value of Mersana Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Mersana Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for MRSN so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Mersana Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether MRSN is over valued or under valued. Whether Mersana Therapeutics Inc is cheap or expensive depends on the assumptions which impact Mersana Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MRSN.

What is Mersana Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Mar 28 2024, MRSN's PE ratio (Price to Earnings) is -3.17 and Price to Sales (PS) ratio is 14.75. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. MRSN PE ratio will change depending on the future growth rate expectations of investors.